The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nektar Therapeutics's revenues will expand 53.3% and EPS will remain in the red.
The average estimate for revenue is $27.5 million. On the bottom line, the average EPS estimate is -$0.43.
Last quarter, Nektar Therapeutics reported revenue of $21.1 million. GAAP reported sales were 34% higher than the prior-year quarter's $15.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.46. GAAP EPS were -$0.46 for Q4 compared to -$0.33 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 65.5%, much about the same as the prior-year quarter. Operating margin was -205.1%, 380 basis points worse than the prior-year quarter. Net margin was -250.3%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $202.6 million. The average EPS estimate is -$1.05.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 195 members out of 223 rating the stock outperform, and 28 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Nektar Therapeutics a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $11.29.
- Add Nektar Therapeutics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Nektar Therapeutics, Franklin Covey, and BP Prudhoe Bay Royalty Trust Jumped Today
Another strong day for the market lifted these names. Get the details here.
The 10 Best Stocks of 2017
Find out how one industry dominated the winners of last year.
The 3 Best Biotech Stocks of 2017
What did it take to rank among the top three biotech stocks this year? At least a 440% gain.